| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664356P | 2018-04-30 | 2018-04-30 | |
| PCT/IB2019/053491WO2019211721A1 (en) | 2018-04-30 | 2019-04-29 | Combinations for treating cancer |
| Publication Number | Publication Date |
|---|---|
| SG11202010528XAtrue SG11202010528XA (en) | 2020-11-27 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202010528XASG11202010528XA (en) | 2018-04-30 | 2019-04-29 | Combinations for treating cancer |
| Country | Link |
|---|---|
| US (1) | US20210030718A1 (en) |
| EP (1) | EP3787620A1 (en) |
| JP (1) | JP2021522246A (en) |
| KR (1) | KR20210005182A (en) |
| CN (1) | CN112040944A (en) |
| AU (1) | AU2019263026B2 (en) |
| BR (1) | BR112020022020A2 (en) |
| CA (1) | CA3097486A1 (en) |
| EA (1) | EA202092540A1 (en) |
| MA (1) | MA52499A (en) |
| MX (1) | MX2020011453A (en) |
| SG (1) | SG11202010528XA (en) |
| TW (1) | TW202014184A (en) |
| WO (1) | WO2019211721A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114728003B (en)* | 2019-11-04 | 2025-01-28 | 阿斯利康(瑞典)有限公司 | Therapeutic combination of acalabrutinib and capasitinib for the treatment of B-cell malignancies |
| BR112022012136A2 (en)* | 2019-12-18 | 2022-08-30 | Zeno Man Inc | MACROCYCLIC COMPOUNDS |
| KR20240019330A (en) | 2021-06-11 | 2024-02-14 | 길리애드 사이언시즈, 인코포레이티드 | Combination of MCL-1 inhibitor and antibody drug conjugate |
| WO2022261301A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202100729T1 (en) | 2011-07-19 | 2022-01-10 | Merck Sharp & Dohme | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors |
| JP2017523207A (en)* | 2014-08-08 | 2017-08-17 | ファーマサイクリックス エルエルシー | Breton tyrosine kinase inhibitor combinations and their use |
| AU2017252222B2 (en)* | 2016-04-22 | 2019-11-07 | Astrazeneca Ab | Macrocyclic Mcl-1 inhibitors for treating cancer |
| CN107056786B (en)* | 2016-10-14 | 2019-05-07 | 苏州明锐医药科技有限公司 | Ah Ka replaces the preparation method of Buddhist nun |
| Publication number | Publication date |
|---|---|
| BR112020022020A2 (en) | 2021-02-02 |
| CA3097486A1 (en) | 2019-11-07 |
| WO2019211721A1 (en) | 2019-11-07 |
| MA52499A (en) | 2021-04-14 |
| KR20210005182A (en) | 2021-01-13 |
| US20210030718A1 (en) | 2021-02-04 |
| AU2019263026A1 (en) | 2020-12-17 |
| CN112040944A (en) | 2020-12-04 |
| TW202014184A (en) | 2020-04-16 |
| JP2021522246A (en) | 2021-08-30 |
| AU2019263026B2 (en) | 2022-06-30 |
| EP3787620A1 (en) | 2021-03-10 |
| EA202092540A1 (en) | 2021-03-17 |
| MX2020011453A (en) | 2020-12-07 |
| Publication | Publication Date | Title |
|---|---|---|
| IL270720A (en) | Combination therapies for treating cancer | |
| EP3641770A4 (en) | Methods for treating cancer | |
| IL273395A (en) | Combination therapies for treating cancer | |
| IL282663A (en) | Bt1718 for use in treating cancer | |
| IL287907A (en) | Methods for treating cancer | |
| IL255060A0 (en) | Combination therapy for treating cancer | |
| EP3407978A4 (en) | Combination therapy for treating cancer | |
| IL277861A (en) | Axl-specific antibodies for cancer treatment | |
| PT3576740T (en) | Cancer treatment | |
| GB201903546D0 (en) | Cancer treatment | |
| EP3892282A4 (en) | Combination for treating cancer | |
| GB201820660D0 (en) | Cancer treatments | |
| EP3706770A4 (en) | Immunotherapeutic combination for treating cancer | |
| SG10202105110VA (en) | Cancer treatment | |
| IL282093A (en) | Combination therapy for cancer | |
| IL268416A (en) | Pharmaceutical combinations for treating cancer | |
| SG11202010528XA (en) | Combinations for treating cancer | |
| IL287652A (en) | Cancer treatment | |
| IL285466A (en) | Cancer treatment | |
| GB201814487D0 (en) | Cancer | |
| IL274626A (en) | Cancer treatment | |
| IL255016A0 (en) | Methods for treating cancer | |
| GB201909468D0 (en) | Compounds for treating cancer | |
| GB201800733D0 (en) | Cancer | |
| GB201707864D0 (en) | Platinum-reistant cancer treatment |